Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ozanimod
Drug ID BADD_D02580
Description Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020.[L12573,L12582] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.[A176474] Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting.[A189336] In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Indications and Usage Ozanimod is indicated for adults in the treatment of relapsing forms of MS, which may include relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive MS.[L12582]
Marketing Status approved; investigational
ATC Code L04AA38
DrugBank ID DB12612
KEGG ID D10968
MeSH ID C000607776
PubChem ID 52938427
TTD Drug ID D07EDB
NDC Product Code Not Available
UNII Z80293URPV
Synonyms ozanimod | RPC1063
Chemical Information
Molecular Formula C23H24N4O3
CAS Registry Number 1306760-87-1
SMILES CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiration abnormal22.02.01.0410.001230%Not Available
Retching07.01.07.0020.000820%Not Available
Rhinorrhoea22.12.03.0210.003279%
Rotator cuff syndrome12.01.07.018; 15.01.08.0020.000940%
Sciatica17.10.03.001; 15.10.01.0010.000530%Not Available
Serotonin syndrome17.05.02.004; 15.05.04.016; 12.03.01.0410.000241%Not Available
Sinus headache22.12.03.022; 17.14.01.0020.000820%
Skin disorder23.03.03.0070.001230%Not Available
Skin lesion23.03.03.0100.002580%Not Available
Skin warm23.03.03.0140.000820%Not Available
Sleep apnoea syndrome17.15.05.001; 22.02.01.013; 19.02.05.0020.001640%
Sleep disorder19.02.04.0010.004219%Not Available
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.001760%Not Available
Stress19.06.02.0040.008921%Not Available
Swelling08.01.03.0150.003279%Not Available
Tenderness08.01.08.0050.000820%Not Available
Tinnitus04.04.01.002; 17.04.07.0040.002170%
Toothache07.09.06.0010.000940%
Transient ischaemic attack24.04.06.005; 17.08.04.0010.000482%
Tremor17.01.06.0020.006389%
Trigeminal neuralgia17.04.08.0010.000241%Not Available
Urinary incontinence17.05.01.008; 20.02.02.0100.001230%
Urinary retention20.02.02.0110.000482%
Urinary tract disorder20.08.01.0010.000820%Not Available
Uterine disorder21.07.01.0060.000241%Not Available
Uveitis06.04.03.003; 10.02.01.0230.000482%
Vertigo17.02.12.002; 04.04.01.0030.001712%
Vision blurred06.02.06.007; 17.17.01.0100.010488%
Visual impairment06.02.10.0130.010802%Not Available
Wheezing22.03.01.0090.001471%
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages